QTERN is a Oral Tablet, Film Coated in the Human Prescription Drug category. It is labeled and distributed by Astrazeneca Pharmaceuticals Lp. The primary component is Dapagliflozin; Saxagliptin Hydrochloride.
| Product ID | 0310-6780_004691c3-02f4-4d9e-abfd-ec3c003537b1 |
| NDC | 0310-6780 |
| Product Type | Human Prescription Drug |
| Proprietary Name | QTERN |
| Generic Name | Dapagliflozin And Saxagliptin |
| Dosage Form | Tablet, Film Coated |
| Route of Administration | ORAL |
| Marketing Start Date | 2017-12-04 |
| Marketing Category | NDA / NDA |
| Application Number | NDA209091 |
| Labeler Name | AstraZeneca Pharmaceuticals LP |
| Substance Name | DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE |
| Active Ingredient Strength | 10 mg/1; mg/1 |
| Pharm Classes | Sodium-Glucose Cotransporter 2 Inhibitor [EPC],Sodium-Glucose Transporter 2 Inhibitors [MoA],Dipeptidyl Peptidase 4 Inhibitor [EPC],Dipeptidyl Peptidase 4 Inhibitors [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2020-12-31 |
| Marketing Start Date | 2017-12-04 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA209091 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2017-12-04 |
| Marketing Category | NDA |
| Application Number | NDA209091 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2017-12-04 |
| Ingredient | Strength |
|---|---|
| DAPAGLIFLOZIN | 10 mg/1 |
| SPL SET ID: | 423c489c-085b-4320-b892-7868ebd6dc6b |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI | |
| UPC Code |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0310-6770 | QTERN | dapagliflozin and saxagliptin |
| 0310-6780 | QTERN | dapagliflozin and saxagliptin |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() QTERN 86344649 4816032 Live/Registered |
AstraZeneca AB 2014-07-22 |